儿科精准医学:进展与优先事项
本文综述儿科精准医学的进展,涵盖药物基因组学、定量药理学和先进治疗药物产品,展示这些创新如何影响临床护理与治疗优化策略,并指出实施面临成本、人力准备、治理与公平性等挑战,需持续实施研究支持整合。
要点
- 药物基因组学可减少儿科处方「试错法」,加速识别安全有效治疗并降低药物毒性。
- 定量药理学通过群体药动-药效建模为危重症和早产儿等特殊人群提供数据驱动剂量指南。
- 模型引导精准给药有望变革治疗药物监测,为药物优化提供循证方法。
核心结论
- 儿科精准医学的潜力已在实践中显现,但实施面临成本、人力准备、治理和公平性等重大挑战。
- 持续的实施研究对于加强证据基础和确定成功整合新技术所需机制至关重要。
研究设计与样本
- 本文为综述,审视儿科精准医学不断演变的格局,考察药物基因组学、定量药理学和先进治疗药物产品的进展。
主要发现
- 药物基因组学变异可影响药物安全性和有效性,在儿科应用有望减少传统「试错法」处方。
- 定量药理学利用定量药理学和专门统计技术(如群体药动-药效建模)根据患者特征优化剂量选择。
- 定量药理学研究可为危重症患者和不同胎龄早产儿等特殊人群提供数据驱动剂量指南。
- 模型引导精准给药有望变革治疗药物监测,提供循证药物优化方法。
- 基因治疗和新型核酸治疗等先进治疗药物产品推动许多严重儿科疾病的治疗进展。
临床怎么用
- 利用药物基因组学减少儿科处方试错,加速识别安全有效治疗并降低药物相关毒性。
- 基于群体药动-药效建模为危重症和早产儿等特殊人群制定数据驱动剂量指南。
- 应用模型引导精准给药变革治疗药物监测,实现循证药物优化。
局限性
- 实施面临成本、人力准备、治理和公平性等重大挑战。
- 需要持续实施研究加强证据基础并确定成功整合新技术所需机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision medicine aims to personalize healthcare, tailoring the clinical approach to each patient's unique profile. This paper reviews the evolving landscape of paediatric precision medicine; examining advances in pharmacogenomics, pharmacometrics and advanced therapy medicinal products; and demonstrating how these innovations can meaningfully influence clinical care and therapeutic optimization strategies. Pharmacogenomics studies how genetic differences can influence an individual's response to drugs. Pharmacogenomic variation can affect both drug safety and efficacy. Utilizing pharmacogenomics in paediatrics has the potential to reduce reliance on the traditional 'trial-and-error' approach to prescribing, accelerating identification of safe and effective treatments, while reducing drug-related toxicity. Pharmacometrics utilizes quantitative pharmacology and specialized statistical techniques-such as population pharmacokinetic-pharmacodynamic modelling-to optimize dose selection based on individual patient's characteristics. Pharmacometric research can deliver data-driven dosing guidelines for special populations, such as critically ill patients and preterm neonates of differing gestations. Furthermore, model-informed precision dosing has the potential to transform therapeutic drug monitoring, providing an evidence-based approach to medicine optimization. Advanced therapy medicinal products, such as gene therapies and novel nucleic acid therapeutics, are driving progress in the treatment of many serious paediatric diseases and highlight the need for innovative funding schemes to address the costs of these remarkable developments. The potential of paediatric precision medicine is already evident in practice. However, implementation presents significant challenges relating to cost, workforce preparedness, governance and equity. Ongoing implementation research is vital to strengthen the evidence base and identify mechanisms required for the successful integration of these novel technologies into paediatric healthcare.
引用
- Husain N, Booth C, Standing JF, et al. Precision medicine in paediatrics: Progress and priorities. Br J Clin Pharmacol. 2026. PMID: 42159076. doi:10.1002/bcp.70573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。